Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 in advanced malignant tumor
NCT04296994Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2020
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iparomlimab + tuvonralimab in advanced malignant solid tumor, sponsored by Qilu Pharmaceutical. Primary endpoint: Safety and tolerability at 21 days. Status: unknown.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT04296994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04296994.